TheraRadar
Data updated: May 26, 2026

Ervebo (ebola zaire vaccine, live)

Approved 2019-12-18
1
Indication
--
Phase 3 Trials
6
Years on Market

Details

Status
Prescription
First Approved
2019-12-18
Patent Cliff
2031

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
Intramuscular
Dosage Forms
Injection

Companies

Active Ingredient: Ebola Zaire Vaccine, Live

Ervebo Approval History

2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2019 to 2019
Dec 2019 ORIGINAL
Update · CBER biologic (Purple Book)

What Ervebo Treats

1 FDA approvals

Originally approved for its first indication in 2019 .

  • Other (1)
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT06841614 EBO-PEP ANRS 0515s EBO-PEP Ph 3 not yet recruiting EBOla Post-Exposure Prophylaxis
NCT05202288 ANRS 0064S IMOVA Ph 2 not yet recruiting Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

Ervebo FDA Label Details

Track Ervebo with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.